SLC39A6 and breast cancer: Overall, they highlight the potential favorable prognostic value of LIV1 expression in early-stage BC, but none of them presented analyses per molecular subtype, nor explored the predictive value for response to chemotherapy or vulnerability/actionability to current or future systemic therapies of BC.